TearLab Announces European Regulatory Clearance for Next-Generation TearLab Discovery ™ System
SAN DIEGO, July 21, 2017 -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (the “Company”) today announced that the commercial version of its next-generation in-vitro diagnostics testing platform, the TearLab Discovery™ System, is in conformity with all the applicable provisions of In Vitro Diagnostic Medical Devices Directive 98/79 EC enabling CE Marking of the device. CE Marking provides clearance in the European Union (EU) and European Free Trade Association (EFTA) member countries.
For the first time, the TearLab next-generation platform offers eye care professionals the ability to assess multiple biomarkers in human tears with a single nanoliter volume tear collection. The lab-on-a-chip platform provides quantitative measurements of tear proteins in a fully automated workflow that is consistent with the current TearLab Osmolarity System, which many physicians have incorporated into their practice. This CE Marking expands regulatory clearance beyond the previously-cleared Discovery device to include the first commercial test card. This test card is capable of measuring three biomarkers, including osmolarity and two inflammatory biomarkers, MMP-9 and IL-1Ra, which together will aid in the diagnosis of dry eye disease and identify patients expected to respond to targeted dry eye disease therapies.
- Published: 21 July 2017
- Written by Editor